- Home
- GNW vs AKRO Comparison
GNW vs AKRO Comparison
Compare GNW & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNW
- AKRO
- Stock Information
- Founded
- GNW 1871
- AKRO 2017
- Country
- GNW United States
- AKRO United States
- Employees
- GNW N/A
- AKRO N/A
- Industry
- GNW Life Insurance
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- GNW Finance
- AKRO Health Care
- Exchange
- GNW Nasdaq
- AKRO Nasdaq
- Market Cap
- GNW 2.9B
- AKRO 2.8B
- IPO Year
- GNW 2004
- AKRO 2019
- Fundamental
- Price
- GNW $6.72
- AKRO $41.00
- Analyst Decision
- GNW
- AKRO Strong Buy
- Analyst Count
- GNW 0
- AKRO 9
- Target Price
- GNW N/A
- AKRO $76.29
- AVG Volume (30 Days)
- GNW 7.4M
- AKRO 1.3M
- Earning Date
- GNW 04-30-2025
- AKRO 05-09-2025
- Dividend Yield
- GNW N/A
- AKRO N/A
- EPS Growth
- GNW 323.28
- AKRO N/A
- EPS
- GNW 0.68
- AKRO N/A
- Revenue
- GNW $7,295,000,000.00
- AKRO N/A
- Revenue This Year
- GNW N/A
- AKRO N/A
- Revenue Next Year
- GNW N/A
- AKRO N/A
- P/E Ratio
- GNW $9.69
- AKRO N/A
- Revenue Growth
- GNW N/A
- AKRO N/A
- 52 Week Low
- GNW $5.87
- AKRO $17.86
- 52 Week High
- GNW $7.90
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- GNW 50.18
- AKRO 53.64
- Support Level
- GNW $6.55
- AKRO $36.46
- Resistance Level
- GNW $6.78
- AKRO $39.59
- Average True Range (ATR)
- GNW 0.30
- AKRO 2.69
- MACD
- GNW 0.02
- AKRO 0.69
- Stochastic Oscillator
- GNW 89.17
- AKRO 93.78
About GNW Genworth Financial Inc
Genworth Financial is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. most of the revenue is generated by the Long-Term Care Insurance segment. The company earns most of its revenue in the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.